紫杉醇

紫杉醇，Paclitaxel (Taxol)，Paclitaxel，是一种新型抗肿瘤剂，是由国家癌症研究所在数千种植物提取物和天然产物中筛选具有抗肿瘤活性的产物时发现的。更多视频请关注视频号【艾维缔】。哔哩哔哩【IVDSHOW】。抖音【军哥聊表观】。

关键词

紫杉醇

所属分类

抑制剂

目录号

A4393

获取报价

IC50和靶点

生物活性描述	Paclitaxel是微管聚合物的稳定剂，在人内皮细胞中的IC50值为0.1 pM。
靶点	Microtubule (human endothelial cells)
生物活性数据	0.1 pM

产品组分

内容	型号	规格	储存温度
紫杉醇	A4393-01	50mg	-20°C
紫杉醇	A4393-02	100mg	-20°C
紫杉醇	A4393-03	500mg	-20°C
紫杉醇	A4393-04	1ml(10mM in DMSO)	-20°C
操作手册	1	1	常温

文件资源

营销中心
注意事项

保存建议厂家推荐蓝冰运输。当您收到产品后，按照说明书建议保存于-20°C。
FAQ
1. Irit Shapira-Netanelov, Olga Furman, et al. "Patient-Derived Gastric Cancer Assembloid Model Integrating Matched Tumor Organoids and Stromal Cell Subpopulations." Cancers (Basel). 2025 Jul 9;17(14):2287 PMID: 40723172

2. Petros A Tyrakis, Domen Kampjut, et al. "Multi - node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models." Br J Cancer. 2025 Aug;133(2):144-154 PMID: 40360883

3. Xiangjuan Wei, Mengyuan Wang, et al. "Internal-External Homologous Drug-Loaded Exosome-Like Nanovesicles Released from Semi-IPN Hydrogel Enhancing Wound Healing of Chemoradiotherapy-Induced Oral Mucositis." Int J Nanomedicine. 2025 Apr 4:20:4105-4121 PMID: 40201151

4. Jiaqiang Xiong, Juyuan Huang, et al. "CpG‐Based Nanovaccines Enhance Ovarian Cancer Immune Response by Gbp2‐Mediated Remodeling of Tumor‐Associated Macrophages." Adv Sci (Weinh). 2025 Apr;12(15):e2412881 PMID: 39985265

5. Lei Li, Shuangshuang Sun, et al. "Metabolic regulation of cytoskeleton functions by HDAC6-catalyzed α-tubulin lactylation." Research Square. 26 Sep, 2024

6. Sanjeev Raghuwanshi, Xu Zhang, et al. "Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies." Cell Death Discov. 2024 May 2;10(1):211. PMID: 38697979

7. Catherine S Snyder, Taylor Repetto, et al. "Co-Delivery Polymeric Poly (Lactic-Co-Glycolic Acid)(PLGA) Nanoparticles to Target Cancer Stem-Like Cells." Methods Mol Biol. 2024:2777:191-204. PMID: 38478345

8. Shengli Dong, Margarite D Matossian, et al. "Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy." Sci Rep. 2023 Jul 22;13(1):11843. PMID: 37481672

9. Aeson Chang, Edoardo Botteri, et al. "Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer." Sci Transl Med. 2023 Apr 26;15(693):eadf1147. PMID: 37099632

10. Schwartz, Hannah, et al. "In vitro Methods to Better Evaluate Drug Responses in Cancer." UMass Chan Medical School. September 8, 2022.

11. Darya A. Stepanova, Vladislava A. Pigareva, et al. "Ultrasonic Film Rehydration Synthesis of Mixed Polylactide Micelles for Enzyme-Resistant Drug Delivery Nanovehicles." Polymers (Basel). 2022 Sep 25;14(19):4013. PMID: 36235958

12. Shengli Dong, Hassan Yousefi, et al. "Ceritinib is a novel triple negative breast cancer therapeutic agent." Mol Cancer. 2022 Jun 29;21(1):138. PMID: 35768871

13. Prateek Bhardwaj, Vikram Gota, et al. "Loco-regional radiosensitizing nanoparticles-in-gel augments head and neck cancer chemoradiotherapy." J Control Release. 2022 Mar;343:288-302. PMID: 35101477

14. Mikhail S. Chesnokov, Marianna Halasi, et al. "Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells." Cell Death Dis. 2021 Jul 14;12(7):704. PMID: 34262016

15. Anirban Roychowdhury, Mayur Jondhale, et al. "Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8." Gene. 2021 Aug 5;792:145728. PMID: 34022297

16. Catherine Suzanne Snyder. "Polymer Nanoparticle Design for Ovarian Cancer Therapies." University of Michigan 2021.

17. Juanwen Lian, Tao Hua, et al. "Interleukin-1β weakens paclitaxel sensitivity through regulating autophagy in the non-small cell lung cancer cell line A549." Exp Ther Med. 2021 Apr;21(4):293. PMID: 33717236

18. Chu xue, Si-Xue Liu, et al. "Corydalis Saxicola Bunting Total Alkaloids Inhibits Paclitaxel-Induced Peripheral Neuropathy By Regulating PKCε-TRPV1 and p38 MAPK-TRPV1 Signaling Pathways." Research Square. doi.org/10.21203/rs.3.rs-332970/v1.

19. Yongman Liu, Jianye Wang, et al. "Quantifying 3D cell–matrix interactions during mitosis and the effect of anticancer drugs on the interactions." Nano Research. ISSN 1998-0124 CN 11-5974/O4.

20. Shahbandi A, Rao SG, et al. "BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer." Cell Death Differ. 2020;10.1038/s41418-020-0564-6. PMID: 32457483

21. Gamache JE, Kemper L, et al. "Developmental pathogenicity of 4-repeat human tau is lost with the P301L mutation in genetically matched tau-transgenic mice." J Neurosci. 2019 Nov 4. pii: 1256-19. PMID: 31685653

22. Tonnessen-Murray CA, Frey WD, et al. "Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival." J Cell Biol. 2019 Sep 17. pii: jcb.201904051. PMID: 31530580

23. Chung HK, Zou X, et al. "A compact synthetic pathway rewires cancer signaling to therapeutic effector release." Science. 2019 May 3;364(6439). PMID: 31048459

24. Zhang Y, Xia F, et al. "miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2." J Exp Clin Cancer Res. 2019 Jan 21;38(1):26. PMID: 30665445

25. Deng Y, Li F, et al. "Triptolide sensitizes breast cancer cells to Doxorubicin through the DNA damage response inhibition." Mol Carcinog. 2018 Jun;57(6):807-814. PMID: 29500880

26. Zina Hamoudi , Thang Manh Khuong, et al. "A fruit fly model for studying paclitaxel-induced pain [version 1;referees: awaiting peer review]" F1000Research 23 Jan 2018, 7:99.

27. Yu Wang，Zhenxin Zhu, et al. "The effect of phenotypic conditioned medium on the proliferation of BGC823 in human gastric cancer cell line." Academic Journal of Second Military Medical University,Dec.2017,Vol.38,No.12.

物理外观	A solid
CAS号	33069-62-4
分子式	C₄₇H₅₁NO₁₄
分子量	853.91
小分子别名	Paclitaxel
溶解度	≥85.6 mg/mL in DMSO; insoluble in H2O; ≥31.6 mg/mL in EtOH with ultrasonic
SMILES	O=C(N[C@H]([C@H](C(O[C@H]1C[C@]2(O)C(C)(C)C([C@@H](OC(C)=O)C([C@@]3(C)[C@]([C@@](CO4)(OC(C)=O)[C@H]4C[C@@H]3O)([H])[C@@H]2OC(C5=CC=CC=C5)=O)=O)=C1C)=O)O)C6=CC=CC=C6)C7=CC=CC=C7
存储条件	-20°C
运输条件	蓝冰
SDF文件	Download SDF

文件下载	文件内容	资源说明
	A4393-紫杉醇	操作手册
	A4393-紫杉醇相关单页	宣传单页

搜索历史清除全部记录

紫杉醇

IC50和靶点

产品组分

文件资源

营销中心

注意事项

FAQ